Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 7/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268751 | 0.78 | ESR1 (0.43) | TAAR1 | |
| SCHEMBL264970 | 0.78 | ADRB2 (0.50) | SCN4A | |
| SCHEMBL7928876 | 0.78 | DPP4 (0.41) | DPP4 | |
| SCHEMBL3715025 | 0.78 | HTR2A (0.46) | TAAR1 | |
| SCHEMBL4709939 | 0.77 | SCN4A (0.45) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL22705600 | 0.77 | SCN4A (0.45) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL2675712 | 0.77 | SCN4A (0.45) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL7406881 | 0.77 | CYP2C19 (0.57) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL898390 | 0.77 | CYP2C19 (0.57) | SCN4ADPP4F2TAAR1 | |
| SCHEMBL4629946 | 0.77 | CYP2C19 (0.57) | SCN4ADPP4F2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354892-A | SIRT5 protein inhibitor and application thereof | 西华大学 | 2023-06-30 | — | — | CN | disclosed |
| US-8431378-B2 | Aminotransferase, gene encoding the same, and methods of using them | KANEKA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20120164724-A1 | NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM | KANEKA CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8133705-B2 | Aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-1889907-B1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | KANEKA CORP (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-1889907-A1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-7098207-B2 | Imidazotriazinones and the use thereof | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-29 | — | — | US | disclosed |
| US-7094911-B2 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-22 | — | — | US | disclosed |
| CN-1234708-C | Novel imidazotriazinones and the use thereof | BAYER AG (DE) | 2006-01-04 | — | — | CN | disclosed |
| US-6878708-B2 | Imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-04-12 | — | — | US | disclosed |
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-20040030132-A1 | New biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | disclosed |
| US-6677360-B2 | TREATMENT AND PROPHYLAXIS OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOPOROSIS AND EYE DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| CN-1407986-A | Novel imidazotriazinones and the use thereof | BAYER AG (DE) | 2003-04-02 | — | — | CN | disclosed |
| US-6420396-B1 | TREATMENT OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOLYTIC DISORDERS, OPHTHALMIC DISORDERS, AND THEIR USE AS INTEGRIN ANTAGONISTS. INHIBITING ANGIOGENESIS | BEIERSDORF AG (DE) | 2002-07-16 | — | — | US | disclosed |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| CN-1334801-A | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER AG (DE) | 2002-02-06 | — | — | CN | disclosed |
| US-4853383-A | β-blocking substituted imidazoles | MERCK & CO., INC. (US) | 1989-08-01 | — | — | US | disclosed |
| US-4642311-A | β-adrenergic blocking imidazolylphenoxy propanolamines | MERCK & CO., INC. (US) | 1987-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030132-A1 | New biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB2, ITGB1, ITGB3 | SCN4A 2869/4885DPP4 3317/4885F2 820/4885 |
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | CYP4F3, CYP4F2, CYP3A7 | SCN4A 300/4885DPP4 1494/4885F2 3504/4885 |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB1, ITGB2, ITGB3 | SCN4A 2927/4885DPP4 2984/4885F2 794/4885 |
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | BCAT1, AGXT, ALDH7A1 | SCN4A 4182/4885DPP4 517/4885F2 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.